Botanix Pharma (ASX:BOT)
- CEO:Vince Ippolito
Botanix Pharma (ASX:BOT) Stock Price
Botanix Pharma (ASX:BOT) Company Overview
Botanix Pharma is an Australian medical dermatology company engaged in the development of cannabinoid-based products for the treatment of a range of skin conditions and are working to get the first cannabinoid products approved by the FDA. If successful, they could dominate a multi-billion dollar dermatology market which has seen few new products approved in the last 20 years.
All products made by Botanix Pharma utilise synthetic CBD in conjunction with PermetrexTM skin delivery technology. PermetrexTM is a dermal delivery formulation technology that allows 10 to 20 times more of the active ingredient to get through the skin to better treat the disease. BOT has exclusive rights to this technology, developed by Dr Eugene Cooper, for all drugs that treat dermatological conditions.
The first two products off the rank target the treatment of Acne (BTX1503) and Atopic Dermatitis (BTX1204). Both drugs are currently in Phase II trials, with outcomes due in late 2019. As it stands right now, there are no cannabis-based products approved for these markets and no-one else is studying the impact of CBD-based products on these conditions.
Should BOT deliver successful endpoints on the Phase II trials for their leading assets, then the most likely outcome from there would be a licensing deal with a global BIG Pharma player that would deliver significant upfront cash flow, and medium-term licensing royalties post successful Phase III study outcomes.
- Address:50 Angove Street North, Perth, WA 6006, Australia
Botanix Pharma (ASX:BOT) Financials
The latest update from the companyClick Here
Stay updated about
Signup to get updates.
Callahan has also worked as an investment director for two venture capital firms focused on investing in life sciences, clean technology and other sectors.
Throughout his career, he has launched more than 20 brands in dermatology and aesthetic medicine, along with playing a leading role in two of the largest dermatology acquisitions—with a combined valuation of $7.8 billion—completed in the past decade.
He is a co-inventor of the NanoCrystal® and SoluMatrix™ technologies, along with being instrumental to the development of the 3 FDA approved products that make use of his delivery system.
In these roles, Peterson oversaw duties relating to finance, business development, business operations and information technology.
Thurn has a background in drug regulation and the biopharmaceutical industry, which has included senior roles with both listed and private companies. He has worked extensively with life science start-ups across a range of technology platforms, as well as having experience in drug discovery, preclinical and clinical development.